BiotechTube

Sepantronium Bromide

Phase 2Active
0 watching 0 views this week⚡ Active
44
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

High-grade B-cell Lymphoma

Conditions

High-grade B-cell Lymphoma, Burkitt Lymphoma, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphatic Diseases, Lymphoma, High-Grade, C-MYC/BCL2 Double-Hit High-Grade B-Cell Lymphoma, C-MYC/BCL6 Double-Hit High-Grade B-Cell Lymphoma, C-Myc Gene Rearrangement

Trial Timeline

Dec 9, 2022 → Jun 30, 2025

NCT ID
NCT05263583

About Sepantronium Bromide

Sepantronium Bromide is a phase 2 stage product being developed by Cothera Bioscience for High-grade B-cell Lymphoma. The current trial status is active. This product is registered under clinical trial identifier NCT05263583. Target conditions include High-grade B-cell Lymphoma, Burkitt Lymphoma, Lymphoma, B-Cell.

Hype Score Breakdown

Clinical
17
Activity
12
Company
2
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT05263583Phase 2Active

Competing Products

8 competing products in High-grade B-cell Lymphoma

See all competitors
ProductCompanyStageHype Score
azenosertibZentalis PharmaceuticalsPhase 2
44
Mirvetuximab SoravtansineAbbViePhase 2
52
Pembrolizumab + Paclitaxel + Carboplatin + Avastin + MK-4830 + DocetaxelMerckPhase 2
52
BMS-986463Bristol Myers SquibbPhase 1
32
MebendazoleBrain BiotechPhase 1
25
Ex-Vivo expanded autologous IL-8 receptor (CXCR2) modified CD70 CAR (8R-70CAR) T cellsBrain BiotechPhase 1
25
APR-246 + Carboplatin and Pegylated Liposomal Doxorubicin Hydrochloride (PLD)Aprea TherapeuticsPhase 1/2
33
APR-246 + Pegylated Liposomal Doxorubicin Hydrochloride (PLD)Aprea TherapeuticsPhase 2
44